Indazole-based compound having synergistic effect on antifungal agent and use thereof
Indazole-based compounds serve as synergistic adjuvants to enhance the antifungal activity of echinocandin agents, addressing the limitations of current antifungal drugs by improving efficacy and reducing side effects and costs, particularly against Aspergillus fumigatus, Candida albicans, and Cryptococcus neoformans.
Patent Information
- Application Number
- PCT/KR2024/003307
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-02-26
- Filing Date
- 2024-03-15
- Publication Date
- 2024-11-21
AI Technical Summary
Current antifungal drugs face issues such as toxicity, drug interactions, and resistance, and have limited effectiveness against certain fungal strains, necessitating the development of new antifungal agents that can enhance antibacterial activity while minimizing side effects.
Development of indazole-based compounds that act as synergistic adjuvants when combined with echinocandin antifungal agents, specifically caspofungin, micafungin, or anidulafungin, to inhibit fungal growth and improve antibacterial activity against pathogens like Aspergillus fumigatus, Candida albicans, and Cryptococcus neoformans.
The indazole-based compounds significantly enhance the antifungal activity of echinocandin agents, reducing the required dosage and costs, while demonstrating superior efficacy against various fungal infections, including Cryptococcus neoformans, when used in combination, thereby improving treatment outcomes.
Smart Images

Figure KR2024003307_21112024_PF_FP_ABST
Abstract
Description
Indazole compounds having synergistic effects against antifungal agents and their uses
[0001] The present invention relates to an indazole compound having a synergistic effect on antifungal agents and a use thereof.
[0002] The recent COVID-19 pandemic has led to an increase in the frequency of fungal infections. This is because patients infected with the coronavirus have weakened immune systems, increasing their risk of infections by pathogenic fungi, which are opportunistic pathogens. Therefore, effective treatment for pathogenic fungi is urgently needed.
[0003] Antifungal drugs are drugs that treat fungal infections by inhibiting the growth and proliferation of fungi. Antifungal drugs currently used as pharmaceuticals are largely classified into three groups: polyenes, azoles, and echinocandins.
[0004] Polyene antifungals insert themselves into the cell membrane and bind to ergosterol, altering its permeability and causing cell contents to leak out, inhibiting fungal growth. Polyene antifungals are among the oldest and most widely used, but they suffer from high toxicity.
[0005] Azole antifungals exhibit antifungal activity by inhibiting the enzyme that synthesizes ergosterol, a major component of the fungal cell membrane. They exert their action by binding to one of the fungal cytochrome P450 (CYP450) enzymes. By broadly inhibiting the CYP450 metabolic enzyme system in the human body, they can interfere with the metabolism of other drugs, leading to drug interactions. Furthermore, they are less effective against pathogenic fungi of the Aspergillus genus.
[0006] Furthermore, the most recently developed echinocandin antifungals inhibit glucan synthase, an enzyme that produces glucan, a major component of the fungal cell wall. This causes pores to form in the cell wall, rendering it unable to withstand osmotic pressure, resulting in antifungal activity. Furthermore, while echinocandin antifungals have minimal side effects, they are very expensive and exhibit a more bacteriostatic effect than a cidal effect.
[0007] As antifungal agents currently being developed and used exhibit various side effects, such as toxicity and resistance, depending on the type of drug, it is necessary to develop new antifungal agents for combination therapy that can improve the antibacterial activity of existing antifungal agents while minimizing these side effects.
[0008] Accordingly, the inventors of the present invention, while conducting research to develop an antifungal adjuvant that can solve the problems of existing antifungal agents, discovered a new antifungal adjuvant that can effectively suppress the growth of fungi by using only a small amount of the antifungal agent when used in combination with an echinocandin antifungal agent, thereby inducing an antibacterial synergy effect of the antifungal agent and improving the bacteriostatic effect of the echinocandin antifungal agent, and confirmed its efficacy, thereby completing the present invention.
[0009] Therefore, the purpose of the present invention is to provide an antifungal adjuvant comprising, as an active ingredient, any one compound selected from the group consisting of chemical formulas 1 to 16 or a pharmaceutically acceptable salt thereof.
[0010] Another object of the present invention is to provide an antifungal combination preparation comprising the antifungal adjuvant of the present invention and an echinocandin antifungal agent as active ingredients.
[0011] Another object of the present invention is to provide a pharmaceutical composition for preventing or treating fungal infection, comprising the antifungal adjuvant of the present invention and an echinocandin antifungal agent as active ingredients.
[0012] Another object of the present invention is to provide a method for inhibiting fungi in vitro, comprising a step of treating an antifungal adjuvant of the present invention in combination with an echinocandin antifungal agent.
[0013] Another object of the present invention is to provide an antifungal composition having antifungal activity against Cryptococcus neoformans, comprising as an active ingredient any one compound selected from the group consisting of chemical formulae 1 to 16 of the present invention or a pharmaceutically acceptable salt thereof.
[0014] Therefore, the present invention provides an antifungal adjuvant comprising, as an active ingredient, any one compound selected from the group consisting of chemical formulas 1 to 16 or a pharmaceutically acceptable salt thereof.
[0015] In one embodiment of the present invention, the compound has a synergistic effect on the antibacterial activity of an antifungal agent and may be administered in combination with an antifungal agent.
[0016] In one embodiment of the present invention, the antifungal agent may be an echinocandin antifungal agent.
[0017] In one embodiment of the present invention, the echinocandin antifungal agent may be caspofungin, micafungin, or anidulafungin.
[0018] In addition, the present invention provides an antifungal combination preparation comprising the antifungal adjuvant according to the present invention and an echinocandin antifungal agent as active ingredients.
[0019] In one embodiment of the present invention, the echinocandin antifungal agent may be caspofungin, micafungin, or anidulafungin.
[0020] In one embodiment of the present invention, the antifungal combination preparation may have antifungal activity against one or more fungi selected from the group consisting of Aspergillus fumigatus, Candida albicans, and Cryptococcus neoformans.
[0021] In addition, the present invention provides a pharmaceutical composition for preventing or treating fungal infection, comprising an antifungal adjuvant according to the present invention and an echinocandin antifungal agent as active ingredients.
[0022] In one embodiment of the present invention, the echinocandin antifungal agent may be caspofungin, micafungin, or anidulafungin.
[0023] In one embodiment of the present invention, the fungus may be Aspergillus fumigatus, Candida albicans, or Cryptococcus neoformans.
[0024] Furthermore, the present invention provides a method for inhibiting fungi in vitro, comprising a step of treating an antifungal adjuvant according to the present invention in combination with an echinocandin antifungal agent.
[0025] In one embodiment of the present invention, the echinocandin antifungal agent may be caspofungin, micafungin, or anidulafungin.
[0026] In one embodiment of the present invention, the fungus may be Aspergillus fumigatus, Candida albicans, or Cryptococcus neoformans.
[0027] In addition, the present invention provides an antifungal composition having antifungal activity against Cryptococcus neoformans, comprising as an active ingredient any one compound selected from the group consisting of chemical formulae 1 to 16 of the present invention or a pharmaceutically acceptable salt thereof.
[0028] The antifungal adjuvant provided in the present invention can effectively inhibit the growth of fungi by using only a small amount of the antifungal agent when used in combination with an echinocandin antifungal agent, thereby inducing an antibacterial synergy effect of the antifungal agent and improving the bacteriostatic effect of the echinocandin antifungal agent. In addition, it has excellent antibacterial activity against fungi resistant to echinocandin antifungal agents, and therefore can be usefully used in the manufacture of an antibacterial composition for preventing fungal infections and a pharmaceutical agent for treating fungal infectious diseases.
[0029] FIG. 1 is a schematic diagram illustrating a process for searching for antifungal adjuvant compounds having a synergistic effect on antifungal agents in one embodiment of the present invention.
[0030] Figure 2 shows the results of screening for an indazole compound that inhibits the growth of a fungus (Candida albicans) when used in combination with caspofungin, an antifungal agent, in one embodiment of the present invention.
[0031] Figure 3 shows the results of analyzing the degree of growth inhibition of fungi (Aspergillus fumigatus) after treatment with caspofungin, an antifungal agent, and NE-G10 compound screened in the present invention at different concentrations, either alone or in combination, in one embodiment of the present invention.
[0032] FIG. 4 shows the results of analyzing the degree of growth inhibition of fungi (Aspergillus fumigatus) in a June plate after treatment with caspofungin, an antifungal agent, and NE-G10 compound screened in the present invention at different concentrations, either alone or in combination, in an embodiment of the present invention. The red numbers in the figure indicate the drug treatment concentrations of each experimental group.
[0033] FIG. 5 is a result confirming that, in one embodiment of the present invention, co-administration of caspofungin and NE-G10 compounds can increase the survival rate of mice infected with a fungus (Aspergillus fumigatus).
[0034] Figure 6 shows the results of analyzing the degree of growth inhibition of fungi (Candida albicans) after treatment with caspofungin, an antifungal agent, and NE-G10 compound screened in the present invention at different concentrations, either alone or in combination, in one embodiment of the present invention.
[0035] Figure 7 shows the results of analyzing the antifungal activity of the indazole compound according to the present invention against the fungus Cryptococcus neoformans, and shows the results compared with the group treated with the antibiotic caspofungin.
[0036] Figure 8 shows the results of analyzing the antifungal activity of the NE-G10 compound and NE-F7 compound screened in the present invention against the fungus Cryptococcus neoformans, and shows the results of comparison with the group treated with existing antibiotics known as caspofungin, voriconazole, and amphotericin B.
[0037] Figures 9 to 12 show the results of analyzing the antifungal activity of the indazole compounds screened in the present invention, and are the results of analyzing the antifungal activity of each compound against the fungi Aspergillus fumigatus, Candida albicans, and Cryptococcus neoformans.
[0038] The present invention is characterized by providing a novel antifungal adjuvant that can further enhance the activity of an antifungal agent and exhibit antibacterial activity more effectively.
[0039] In order to develop a new antifungal adjuvant that can improve the low antibacterial effect, which is a problem of existing antifungal agents, while lowering the unit cost of use and achieving economical effects, the inventors screened compounds that can induce antibacterial synergy effects of antifungal agents among approximately 8,000 compounds distributed from the Korea Chemical Bank.
[0040] In one embodiment of the present invention, 16 compounds were discovered that showed an effect of further enhancing antifungal activity when used in combination with an antifungal agent against Aspergillus fumigatus, Candida albicans, and Cryptococcus neoformans fungi.
[0041] In particular, the 16 compounds screened in the present invention were confirmed as compounds belonging to the indazole family as a result of structural analysis, and these compounds were found to inhibit fungal growth much more effectively when used in combination with caspofungin antibiotics than when used alone, and exhibited even better antifungal activity than when used alone with caspofungin.
[0042] Therefore, the present invention screened for a new antifungal adjuvant capable of inducing antibacterial synergistic activity of an antifungal agent, and the 16 new antifungal adjuvant compounds screened are compounds represented by the following chemical formulas 1 to 16.
[0043] Therefore, the present invention is characterized in providing an antifungal adjuvant comprising, as an active ingredient, any one compound selected from the group consisting of the following chemical formulas 1 to 16 or a pharmaceutically acceptable salt thereof.
[0044]
[0045] The compound of the present invention can be used in the form of a pharmaceutically acceptable salt, and as a salt, an acid addition salt formed by a pharmaceutically acceptable free acid is useful. The acid addition salt is obtained from inorganic acids such as hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid, hydrobromic acid, hydroiodic acid, nitrous acid or phosphorous acid, and non-toxic organic acids such as aliphatic mono- and dicarboxylates, phenyl-substituted alkanoates, hydroxyalkanoates and alkanedioates, aromatic acids, aliphatic and aromatic sulfonic acids. These pharmaceutically non-toxic salts include sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, nitrates, phosphates, monohydrogen phosphates, dihydrogen phosphates, metaphosphates, pyrophosphate chlorides, bromides, iodides, fluorides, acetates, propionates, decanoates, caprylates, acrylates, formates, isobutyrates, caprates, heptanoates, propiolates, oxalates, malonates, succinates, suberates, sebacates, fumarates, maleates, butyn-1,4-dioate, hexane-1,6-dioate, benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates, hydroxybenzoates, methoxybenzoates, phthalates, Contains terephthalate, benzenesulfonate, toluenesulfonate, chlorobenzenesulfonate, xylenesulfonate, phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate, β-hydroxybutyrate, glycolate, malate, tartrate, methanesulfonate, propanesulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate or mandelate.
[0046] In the present invention, the “antifungal adjuvant” is also called an “antimicrobial adjuvant” and refers to a substance that increases the susceptibility of harmful bacteria to antifungal or antibacterial agents by suppressing the resistance of harmful bacteria to antibacterial agents or inducing intracellular accumulation of antibacterial agents, even if it does not directly kill the harmful bacteria.
[0047] The antifungal adjuvant screened in the present invention has the characteristic of having antibacterial synergistic activity specific to echinocandins antifungal agents, and can be used in combination with echinocandins antifungal agents.
[0048] Antifungal agents are also used as drugs to treat fungal infections by inhibiting the growth and proliferation of fungi, and are broadly classified into polyenes, azoles, and echinocandins.
[0049] Meanwhile, the compound screened as an antifungal adjuvant of the present invention uniquely does not exhibit synergistic efficacy against polyene and azole antifungal agents, while exhibiting specific synergistic efficacy only against echinocandins antifungal agents.
[0050] The antifungal adjuvant of the present invention may be an echinocandin-based antifungal agent that induces a synergistic effect, but is not limited thereto, and may be caspofungin, micafungin, or anidulafungin, and preferably caspofungin.
[0051] In addition, the present invention can provide an antifungal combination preparation comprising the antifungal adjuvant of the present invention and an echinocandin antifungal agent as active ingredients.
[0052] The antifungal combination preparation according to the present invention is a composition prepared so that any one antifungal adjuvant selected from the group consisting of the chemical formulae 1 to 16 screened in the present invention and an echinocandin antifungal agent can be administered together, and induces antibacterial activity against fungi, such as inhibiting fungal growth or inducing fungal cell death.
[0053] The echinocandin antifungal agent that may be included in the antifungal combination preparation of the present invention may include, but is not limited to, caspofungin, micafungin, or anidulafungin.
[0054] In one embodiment of the present invention, the activity of the screened antifungal adjuvant compounds of the present invention as antifungal adjuvants was analyzed, and it was found that the 16 compounds showed a greater enhancement of fungal growth inhibition activity when used in combination with caspofungin than when used alone, and in particular, the NE-G10 compound of chemical formula 2 showed excellent antifungal enhancing activity against both Aspergillus fumigatus and Candida albicans fungi when used in combination with caspofungin.
[0055] In addition, the present invention can provide a pharmaceutical composition for preventing or treating fungal infection, comprising an antifungal adjuvant according to the present invention and an echinocandin antifungal agent as active ingredients.
[0056] As described above, the antifungal adjuvant according to the present invention can effectively inhibit the growth of fungi and induce the death of fungi by inducing an antibacterial synergy effect of an echinocandin-based antifungal agent.
[0057] The pharmaceutical composition for preventing or treating fungal infection according to the present invention has a preventive, improving or treating effect on diseases induced by fungal infection.
[0058] Preferably, the fungus may be Aspergillus fumigatus, Candida albicans or Cryptococcus neoformans, and the disease may include all diseases caused by infection with Aspergillus fumigatus, Candida albicans or Cryptococcus neoformans.
[0059] Aspergillus fumigatus is a representative Aspergillus fungus that infects immunocompromised individuals. Its colonies are grayish-green in color and are known to cause disease when airborne spores enter the lungs. Diseases specifically caused by Aspergillus fumigatus infection include, but are not limited to, aspergillosis, asthma, aspergilloma, and allergic alveolitis.
[0060] Also, Candida albicans mainly multiplies in epithelial cells in the human body. Candida albicans exists in normal skin, mucous membranes, feces, sputum, urine, etc. and is harmless to the human body, but when antibiotics or adrenal cortex hormones are used, or when the body's immunity is weakened, it can grow abnormally and cause disease. In addition, it can cause local mucosal inflammation such as stomatitis and vaginitis, or progress to systemic infection. Types of candidiasis caused by Candida albicans include mucosal candidiasis, which causes sores and pain in the corners of the mouth, tongue, vulva, and vagina; cutaneous candidiasis, which causes red sores between skin folds, between the fingers, around the anus, or breasts; gastrointestinal candidiasis, which causes diarrhea, abdominal pain, and jaundice; and systemic candidiasis, which presents symptoms similar to sepsis and is accompanied by meningitis or endocarditis.
[0061] Additionally, Cryptococcus neoformans is a fungus belonging to the class Heterozygosauria, and is widely found in various natural environments, including seawater, freshwater, soil, trees, livestock and bird excrement, in most parts of the world.
[0062] Human infection was first reported in 1894, and it is known to cause acute, subacute, and chronic infections of the lungs, meninges, and systemic tracts. Infection with Cryptococcus neoformans occurs naturally when yeast-like cells are inhaled into the lungs, and it commonly infects immunocompromised patients, but it can also infect patients without preexisting conditions. In hosts with normal immunity, the initial infection produces pulmonary granulomas and induces an antibody response, whereas in patients with compromised immune functions due to organ transplantation or acquired immunodeficiency syndrome (AIDS), it is known to infect the central nervous system (CNS) and cause meningitis, and it has been identified as a major cause of death in AIDS worldwide.
[0063] The pharmaceutical composition of the present invention may include a pharmaceutically acceptable additive, and as the pharmaceutically acceptable additive, starch, gelatinized starch, microcrystalline cellulose, lactose, povidone, colloidal silicon dioxide, calcium hydrogen phosphate, lactose, mannitol, maltose, gum arabic, pregelatinized starch, corn starch, powdered cellulose, hydroxypropyl cellulose, Opadry, sodium starch glycolate, carnauba wax, synthetic aluminum silicate, stearic acid, magnesium stearate, aluminum stearate, calcium stearate, white sugar, etc. may be used.
[0064] The pharmaceutically acceptable additive according to the present invention is preferably included in an amount of 0.1 to 90 parts by weight in the composition, but is not limited thereto.
[0065] In the present invention, the composition can be administered in various oral or parenteral dosage forms during actual clinical administration. When formulating, it can be prepared using diluents or excipients such as commonly used fillers, bulking agents, binders, wetting agents, disintegrants, and surfactants. It is preferable to use suitable formulations known in the art as disclosed in a literature (Remington's Pharmaceutical Science, recently, Mack Publishing Company, Easton PA). Carriers, excipients and diluents that may be included in the composition include lactose, dextrose, sucrose, oligosaccharides, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxy benzoate, propylhydroxy benzoate, talc, magnesium stearate, mineral oil and the like.
[0066] The above solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and these solid preparations are prepared by mixing at least one excipient, such as starch, calcium carbonate, sucrose or lactose, gelatin, etc. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. In addition, the above liquid preparations for oral administration include suspensions, oral solutions, emulsions, syrups, etc., and in addition to commonly used simple diluents such as water and liquid paraffin, various excipients such as wetting agents, sweeteners, fragrances, preservatives, etc. may be included.
[0067] The above preparations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized preparations, and suppositories.
[0068] Non-aqueous solvents and suspensions may include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate. Suppository bases may include witepsol, macrogol, tween 61, cacao butter, laurin butter, and glycerogelatin. The parenteral administration may be administered externally or by intraperitoneal injection, rectal injection, subcutaneous injection, intravenous injection, intramuscular injection, or intrathoracic injection.
[0069] The composition of the present invention can be administered in a pharmaceutically effective amount.
[0070] The above 'pharmaceutically effective amount' means an amount sufficient to treat a disease with a reasonable benefit / risk ratio applicable to medical treatment, and the effective dosage level can be determined based on factors including the type and severity of the individual, age, sex, type of virus infected, activity of the drug, sensitivity to the drug, time of administration, route of administration and excretion rate, duration of treatment, concurrently used drugs, and other factors well known in the medical field.
[0071] The composition of the present invention can be administered as an individual treatment or in combination with other treatments, and can be administered sequentially or simultaneously with conventional treatments. It can be administered singly or in multiple doses. Taking all of the above factors into account, it is important to administer the amount that achieves maximum effect with the minimum amount possible without causing side effects, a determination readily made by those skilled in the art.
[0072] The term 'administration' used in the present invention means providing a predetermined composition of the present invention to an individual by any appropriate method.
[0073] In the present invention, the composition can be administered to a subject via various routes. Any route of administration is conceivable, including oral, rectal, intravenous, intramuscular, subcutaneous, intrauterine, or intracerebrovascular injection.
[0074] In the present invention, 'prevention' means any act of suppressing fungal infection or delaying the onset of a fungal infection disease by administering a composition.
[0075] In the present invention, 'improvement' means any act of improving or beneficially changing symptoms caused by fungal infection by administration of a composition.
[0076] In the present invention, 'treatment' means all acts of curing a fungal infection disease by administering a composition.
[0077] Furthermore, the present invention can provide a method for inhibiting fungi in vitro, comprising a step of treating the antifungal adjuvant of the present invention in combination with an echinocandin antifungal agent.
[0078] The above fungus may be one or more selected from the group consisting of Aspergillus fumigatus, Candida albicans and Cryptococcus neoformans.
[0079] In addition, the above combination treatment means treating the antifungal adjuvant and the echinocandin antifungal agent together rather than alone, such as treating the antifungal adjuvant and the echinocandin antifungal agent simultaneously or treating these components sequentially.
[0080] When the antifungal adjuvant screened in the present invention is used in combination, fungi can be effectively suppressed even at a concentration much lower than the treatment concentration of existing echinocandin antifungal agents, thereby reducing the amount of echinocandin antifungal agents used and simultaneously reducing costs.
[0081] Furthermore, the present invention is characterized by providing an antifungal composition having antifungal activity against Cryptococcus neoformans, which comprises as an active ingredient any one compound selected from the group consisting of chemical formulae 1 to 16 of the present invention or a pharmaceutically acceptable salt thereof.
[0082] The inventors of the present invention analyzed whether the 16 indazole compounds screened in the present invention had antifungal activity that inhibited the growth of the Cryptococcus neoformans fungus. As a result, it was confirmed that the indazole compound of the present invention had excellent antifungal activity against Cryptococcus neoformans when treated alone, even without combined treatment with antibiotics.
[0083] Therefore, the indazole compound of the present invention can be used as an antifungal agent against the fungus Cryptococcus neoformans by itself.
[0084] Hereinafter, the present invention will be described in more detail through examples. These examples are intended to more specifically illustrate the present invention, and the scope of the present invention is not limited to these examples.
[0085]
[0086] <Preparation example and experimental method>
[0087] (1) 96-well plate growth assay
[0088] Prepare the drug (antifungal adjuvant compound) to be used in the experiment by dissolving it in DMSO at a concentration of 10 mM (prepare in 1 mL volume). Prepare a drug at a concentration of 0.4 mM to make the final concentration in the first well of the 96-well plate 10 uM. Add the 0.4 mM drug to the first well of the 96-well plate and dilute the drug to half the concentration in the second well using DMSO (for example, add 100 μl of 0.4 mM drug to the first well, add 50 uL DMSO to the second well, and then transfer 50 uL of drug from the first well to the second well and mix). Perform serial dilutions of 2-fold up to a total of 8 wells. After that, dispense 5 uL of the prepared drug into each new sterilized 96-well plate. The control group is the group treated with DMSO only. Since approximately 20 mL of medium is used per plate, 20 mL of CM medium is transferred to a falcon tube and caspofungin, an echinocandin-type drug, is treated at a concentration of 0.5 μg / mL (10 μg per 20 mL). Afterwards, 2 x 10 Conidia stock (0.01% Tween) is added. 5 After adjusting the number of bacteria to 4 / mL, add them to 20 mL of CM medium treated with caspofungin (4x10 for 20 mL) 6 Then, add the prepared medium containing conidia to the container and dispense 200 μL into each 96-well plate containing 5 μL of each drug using a multi-pipette. Seal tightly with plastic wrap and aluminum foil, incubate at 37°C, and take a photograph to confirm the degree of fungal growth.
[0089]
[0090] (2) 6-well plate spotting assay
[0091] MM agar medium or YPD agar medium is prepared, and caspofungin is treated at a concentration of 0.5 ug / mL, and 20 mL is dispensed into each 50 mL tube. The drug to be used (the antifungal adjuvant candidate drug of the present invention) is then diluted by 1 / 2 unit from the final concentration of 5 μM and treated into the dispensed tubes. At this time, the medium treated with only 0.5 ug / mL of caspofungin and 100 μL of DMSO and the untreated medium were used as controls. 5 mL of the prepared medium is dispensed into each sterilized 6-well plate, and after solidification, 5 x 10 conidia of A. fumigatus are added. 3 Each cell was spotted, and C. albicans and C. neoformans were spotted at OD600=0.01 and analyzed.
[0092]
[0093] (3) Animal testing
[0094] A. fumigatus spores were cultured on solid MM medium at 37°C for 5 days. Spores were collected using 0.9% saline containing 0.01% Tween 80. Five-week-old male BALB / C mice were purchased and allowed to acclimate to the environment for 1 week. All mice weighed 18–20 g when immunosuppression was performed. For immunosuppression, mice were injected with 150 mg / kg of cyclophosphamide 4 days before fungal infection, and injections were continued at 3-day intervals (days -4, -1, +1, +4, and +7 after infection). Cortisone (112 mg / kg) was injected once the day before fungal infection, and mice were anesthetized using isoflurane, an inhalant anesthetic, during fungal infection. Mice were infected intranasally with 5 x 10^5 conidia, and 1 mg / kg caspofungin was injected intraperitoneally 24 hours after fungal infection. Next, NE-G10, an indazole compound of the present invention, was dissolved in 20% HP-β-CD at 5 mg / kg and administered orally. The compound was administered daily until the end of the experiment. The mice were monitored, and the survival rate was recorded daily. Tetracycline (1 g / L) was administered to prevent bacterial infection. Mice that survived at the end of the experiment were euthanized with carbon dioxide gas in accordance with the guidelines of the Institutional Animal Care and Use Committee (IACUC) of Korea University.
[0095]
[0096] <Example 1>
[0097] Discovery of compounds with a synergic effect that enhances the antibacterial activity of echinocandins antifungal agents.
[0098] Despite their many advantages, echinocandin antifungals have been limited in their use due to their high price and their bacteriostatic rather than cidal effects. Therefore, the inventors of the present invention conducted the following experiments to identify antifungal adjuvants that could enhance the antifungal activity of echinocandin antifungals while simultaneously improving their bacteriostatic effects. This study was conducted using a compound library provided by the Korea Chemical Bank.
[0099] Candidate substances were searched using the method shown in Figure 1 based on approximately 8,000 compounds provided by the Korea Compound Bank, and the compound library used in this experiment was provided by the Korea Compound Bank (www.chembank.org).
[0100] Specifically, after treating the candidate substance together with caspofungin, an echinocandin antifungal agent, against the fungus Aspergillus fumigatus and the fungus Candida albicans, a candidate substance that can enhance the antifungal activity of caspofungin was selected.
[0101] More specifically, Aspergillus fumigatus was cultured in media co-treated with the antifungal agent caspofungin (0.5 μg / ml) and the candidate compound (6.2 μM), and the growth status was analyzed. In addition, a group treated with the antifungal agent caspofungin alone was used for comparison.
[0102] In addition, Candida albicans was cultured in a medium co-treated with caspofungin antifungal (0.01 ug / ml) and candidate compound (6.2 uM), and the growth status was analyzed.
[0103] The results of the above analysis are shown in Table 1 below.
[0104] [Correction pursuant to Rule 91, May 8, 2024]
[0105] [Correction pursuant to Rule 91, May 8, 2024]
[0106] [Correction pursuant to Rule 91, May 8, 2024]
[0107] [Correction pursuant to Rule 91, May 8, 2024]
[0108]
[0109] As a result, as described in Table 1 above, the results of the antifungal activity analysis against Aspergillus fumigatus showed that when each compound was treated alone, it had antifungal activity that inhibited the growth of Aspergillus fumigatus, and in particular, among the compounds in Table 1, in the case of compound ⑥, the antifungal activity against Aspergillus fumigatus was found to be significantly increased in the group treated together with caspofungin compared to the group treated alone with the compound.
[0110] In addition, the results of the antifungal activity analysis against Candida albicans showed that most of the groups treated with the compound alone did not inhibit the growth of Candida albicans, whereas among the candidate compounds in Table 1, compounds No. 4, No. 6, No. 8, No. 11, No. 12, No. 13, No. 17, No. 18, No. 20, No. 22, No. 23, No. 26, No. 29, No. 30, No. 32 and No. 33 showed enhanced antifungal activity against Candida albicans when treated together with caspofungin (see Fig. 2).
[0111]
[0112] Therefore, the present inventors confirmed through the above results that the above 16 compounds can be used as auxiliary antifungal agents that can further enhance the antifungal activity of caspofungin, an antifungal agent of the echinocandin series, when used in combination with caspofungin, and that these compounds correspond to indazole compounds, and in particular, compound ⑥ was shown to exhibit the best antifungal activity against both Aspergillus fumigatus and Candida albicans when used in combination with caspofungin. Accordingly, the present inventors named compound ⑥ as the "NE-G10" compound.
[0113]
[0114] <Example 2>
[0115] Analysis of synergistic antibacterial activity of the indazole compound of the present invention against echinocandins antifungal agents
[0116]
[0117] <2-1> Antifungal activity analysis against Aspergillus fumigatus
[0118] Among the compounds with antifungal activity discovered through the above <Example 1>, an experiment was conducted to reconfirm whether NE-G10 compound (compound 6), which showed the best antifungal activity when used in combination with caspofungin, had synergistic antibacterial activity against antifungal agents.
[0119] To this end, the growth of Aspergillus fumigatus was analyzed after co-treatment with NE-G10 compound (5, 2.5, 1.2, 0.6, 0.3, 0.15, 0.08, 0.04 uM) and caspofungin (CAS) antifungal agent (0.1, 0.5, 1.0 ug / ml) at various concentrations in a 96-well plate. At this time, a group treated only with DMSO and a group treated only with NE-G10 compound were used as controls, respectively.
[0120] As a result, as shown in Fig. 3, in the control group treated with only DMSO, all Aspergillus fumigatus fungi were found to have grown, and in the group treated with only the NE-G10 compound and the group treated with only caspofungin, Aspergillus fumigatus fungi also grew, whereas in the group treated with the NE-G10 compound and caspofungin in combination, the growth inhibition activity of Aspergillus fumigatus was found to be significantly superior to the group treated with them alone.
[0121] In addition, as a result of visual analysis of antifungal activity in solid media of 6-well plates, as shown in Fig. 4, in the control group treated with DMSO only, it was confirmed that Aspergillus fumigatus fungi had sufficiently grown after 48 hours of incubation. On the other hand, when caspofungin was treated alone, the growth of Aspergillus fumigatus was inhibited starting from a treatment concentration of 0.1 ug / ml, and the growth was most inhibited at treatment concentrations of 0.5 and 1.0 ug / ml. However, after 96 hours of incubation, the growth of Aspergillus fumigatus fungi was found to recover again even when caspofungin was treated at various concentrations.
[0122] Meanwhile, when caspofungin was co-treated with various concentrations of 0.5 ug / ml and NE-G10 compound, the growth of Aspergillus fumigatus was found to be very slow when NE-G10 compound was co-treated with 0.62 uM, and no growth of the fungus was observed even after 96 hours of incubation.
[0123] Through this, the inventors of the present invention were able to find out that when the indazole compounds screened in the present invention are used in combination with an echinocandin-based antifungal agent, not only can a synergistic effect be achieved that can efficiently increase the antibacterial activity of the echinocandin-based antifungal agent, but also excellent antifungal activity can be induced while reducing the amount of the echinocandin-based antifungal agent used.
[0124]
[0125] Furthermore, the inventors of the present invention conducted an experiment to verify the antifungal effect of the indazole compound of the present invention through animal experiments. Specifically, 5-week-old male BALB / c mice were purchased and injected with cyclophosphamide (150 mg / kg body weight) once every 3 days starting on the 4th day to suppress the immune system, and on the 1st day, hydrocortisone acetate (112.5 mg / kg body weight) was injected. After anesthetizing the mice with isoflurane inhalation, they were infected intranasally with one drop of 20 μl of a spore solution containing 5 x 10^5 conidia. One drop of the spore solution was instilled into the nose of the anesthetized mice so that the mice could inhale the solution without pain. Eight mice were used in each experimental group, and two independent experiments were performed. Twenty-four hours after infection, caspofungin 1 mg / kg and NE-G10 5 mg / kg were administered orally daily, either alone or in combination, as shown in Figure 4. When only one drug was administered, 20% hydroxypropyl-b-cyclodextrin, a solvent used to dissolve the drug, was administered instead of the drug.
[0126]
[0127] As a result, as shown in Fig. 5, mice infected with A. fumigatus began to die 5 days after infection, despite being administered NE-G10, 6 mice died 6 days after infection, and all mice died 8 days after infection, showing a survival rate of 0%. Mice that were not administered drugs after infection began to die 4 days after infection, and all mice also died 10 days after infection, showing a survival rate of 0%. Mice administered caspofungin began to die 6 days after infection, and 12.5% of mice survived 10 days after infection.
[0128] In contrast, all mice in the group co-administered with caspofungin and NE-G10 began to die after 6 days, and 25% of the mice survived 10 days after infection.
[0129] Through this, the inventors of the present invention were able to more clearly confirm that the indazole compound of the present invention can induce a synergistic effect on the antifungal effect of caspofungin.
[0130]
[0131] <2-2> Antifungal activity analysis against Candida albicans
[0132] Furthermore, the inventors of the present invention conducted an experiment to reconfirm the synergistic effect of an antifungal agent according to the combined treatment of the indazole compound of the present invention against Candida albicans. The experiment was conducted under the same conditions as in the 96-well plate of <2-1> above, but Candida albicans was used as the fungus.
[0133]
[0134] As confirmed in Example 1 above, among the indazole compounds discovered in the present invention, 16 compounds showed significantly increased antifungal activity when treated together with caspofungin compared to the group treated alone (Table 1 above).
[0135] Among the 16 compounds that increased antifungal activity when combined, the following experiment was performed on the NE-G10 compound.
[0136] On a solid medium, after Candida albicans fungi were seeded, the antifungal activity against Candida albicans fungi was analyzed for groups treated with different concentrations of caspofungin alone, groups treated with NE-G10 compound alone, and groups treated with different concentrations of NE-G10 compound in combination with caspofungin.
[0137]
[0138] As a result, as shown in Fig. 6, in the group treated with the NE-G10 compound alone and the group treated with caspofungin alone, the fungus Candida albicans still grew, whereas in the group treated with the NE-G10 compound and caspofungin in combination, significantly improved antifungal activity was confirmed compared to the group treated with the drug alone (Fig. 6A).
[0139] In addition, as shown in Fig. 6B, when only 0.01 ug / ml - 0.02 ug / ml of caspofungin was treated, C. albicans fungus was found to grow actively, indicating that antifungal activity against C. albicans was insufficient. When caspofungin and various concentrations of NE-G10 compound were treated, it was confirmed that the growth of C. albicans was effectively inhibited.
[0140] These results show that when the indazole compound of the present invention is treated together with the antifungal agent caspofungin, the indazole compound of the present invention can increase the antibacterial activity of the antifungal agent, thereby inducing a synergistic effect on the antifungal activity against C. albicans.
[0141]
[0142] <2-3> Antifungal activity analysis against Cryptococcus neoformans
[0143] The present inventors performed a plate assay experiment to confirm whether the indazole compound of the present invention has antifungal activity against the fungus Cryptococcus neoformans (C. neoformans) in addition to A. fumigatus and C. albicans.
[0144]
[0145] As a result, as shown in Fig. 7, the indazole compound of the present invention was found to have excellent antifungal activity against the fungus C. neoformans, and this antifungal activity was found to be superior to that of the groups treated with the indazole compound of the present invention in combination with caspofungin.
[0146]
[0147] In addition, the inventors of the present invention compared the antifungal activity of NE-G10 and NE-F07 compounds among the indazole compounds of the present invention with the activity of antifungal agents. At this time, the antifungal agents used were caspofungin, voriconazole of the azole family, and amphotericin B of the polyene family.
[0148]
[0149] As a result, as shown in Fig. 8, interestingly, C. neoformans fungi showed high resistance to caspofungin, indicating that the fungi grew well despite caspofungin treatment. On the other hand, the groups treated with voriconazole, an azole, and amphotericin B, a polyene, did not show resistance to these antibiotics, indicating that the growth of the fungi was inhibited (the MICs of voriconazole and amphotericin B were 0.63 and 1.25, respectively).
[0150] On the other hand, the group treated with NE-G10 and NE-F07, which are indazole compounds of the present invention, showed better antifungal activity than the above antibiotics, and the MICs of NE-G10 and NE-F07 against C. neoformans were 1.25 and 0.31, respectively.
[0151] The results of analyzing the antifungal activity of the indazole compounds of the present invention against three types of fungi performed in the above examples of the present invention (MIC analysis) are shown in FIGS. 9 to 12.
[0152]
[0153] Through these results, the inventors of the present invention were able to find that the indazole compound of the present invention exhibited excellent antifungal activity against C. neoformans fungus alone without the need for combined treatment with antibiotics, and thus could be usefully used as a single antifungal agent against C. neoformans fungus.
[0154]
[0155] The indazole compounds discovered in the present invention showed antifungal activity against the fungus Cryptococcus neoformans (C. neoformans) in addition to A. fumigatus and C. albicans, and thus, it was found that they can be usefully used as antifungal agents that act on various pathogenic fungi.
[0156]
[0157] The present invention has been described above, focusing on preferred embodiments thereof. Those skilled in the art will appreciate that the present invention can be implemented in modified forms without departing from its essential characteristics. Therefore, the disclosed embodiments should be considered illustrative rather than limiting. The scope of the present invention is set forth in the claims, not the foregoing description, and all differences within the scope equivalent thereto should be construed as being encompassed by the present invention.
Claims
1. An antifungal adjuvant comprising, as an active ingredient, any one compound selected from the group consisting of the following chemical formulas 1 to 16 or a pharmaceutically acceptable salt thereof.
2. In paragraph 1, An antifungal adjuvant, characterized in that the compound has a synergistic effect on the antibacterial activity of an antifungal agent and is administered in combination with an antifungal agent.
3. In paragraph 1, An antifungal adjuvant, characterized in that the above antifungal agent is an echinocandin antifungal agent.
4. In paragraph 3, An antifungal adjuvant, characterized in that the echinocandin antifungal agent is caspofungin, micafungin or anidulafungin.
5. An antifungal combination preparation comprising the antifungal adjuvant of paragraph 1 and an echinocandin antifungal agent as active ingredients.
6. In paragraph 5, An antifungal combination preparation characterized in that the echinocandin antifungal agent is caspofungin, micafungin, or anidulafungin.
7. In paragraph 5, An antifungal combination preparation characterized in that the above antifungal combination preparation has antifungal activity against one or more fungi selected from the group consisting of Aspergillus fumigatus, Candida albicans, and Cryptococcus neoformans.
8. A pharmaceutical composition for preventing or treating fungal infection, comprising the antifungal adjuvant of paragraph 1 and an echinocandin antifungal agent as active ingredients.
9. In paragraph 8, A pharmaceutical composition for preventing or treating fungal infection, characterized in that the echinocandin antifungal agent is caspofungin, micafungin or anidulafungin.
10. In paragraph 8, A pharmaceutical composition for preventing or treating a fungal infection, characterized in that the fungus is Aspergillus fumigatus, Candida albicans or Cryptococcus neoformans.
11. A method for inhibiting fungi in vitro, comprising a step of treating the antifungal adjuvant of paragraph 1 in combination with an echinocandin antifungal agent.
12. In paragraph 11, A method for inhibiting fungi in vitro, characterized in that the echinocandin antifungal agent is caspofungin, micafungin or anidulafungin.
13. In paragraph 11, A method for inhibiting fungi in vitro, characterized in that the fungus is Aspergillus fumigatus, Candida albicans or Cryptococcus neoformans.
14. A composition comprising, as an active ingredient, any one compound selected from the group consisting of the following chemical formulas 1 to 16 or a pharmaceutically acceptable salt thereof. An antifungal composition having antifungal activity against Cryptococcus neoformans.
Citation Information
Patent Citations
Synergist for antifungal drugs
CN115120602A
Composition for preventing or treating inflammatory diseases comprising mimetic compounds of N8 peptide, an N-terminal 8-amino acid peptide derived from p22phox as an active ingredient
KR1020170091040A
